Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicenter Clinical Trail of Efficacy and Safety of Short Course Radiotherapy Combined With CAPOX and PD-1/CTLA-4 Bispecific Antibody QL1706 in Patients With Liver Metastases From Rectal Cancer

NCT06787183 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT06787183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06787183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicenter Clinical Trail of Efficacy and Safety of Short Course Radiotherapy Combined With CAPOX and PD-1/CTLA-4 Bispecific Antibody QL1706 in Patients With Liver Metastases From Rectal Cancer
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
December 1, 2025
Completion date
December 1, 2029
Enrollment
42 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced rectal cancer with liver metastases